Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. (5th April 2019)

• Record Type: Journal Article
• Authors: Barahona, Maria J; Baratta, Vanessa; Ollodart, Jenna; Mulligan, David; Geibel, John P
• Is Part Of: Future medicinal chemistry. Volume 11:Number 8(2019)
• Page Start: 847
• Page End: 855
• Publication Date: 2019-04-05
• Subjects: calcium-sensing receptor -- gastrointestinal disorders -- inflammation -- nanoparticles -- nutraceutical -- pharmaceutical; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc-2018-0313
• Languages: English
• ISSNs: 1756-8919

Abstract

Gastrointestinal illnesses pose a significant worldwide disease burden and are associated with an array of medicinal and surgical therapies. Standard pharmaceutical options have adverse effects, prompting the rise of nutraceutical or food-derivative therapies. Here, we present an overview of the current nutraceutical therapies in gastrointestinal disease. We then introduce the calcium-sensing receptor (CaSR) as a novel therapeutic target. A G-protein-coupled receptor found in apical and basal intestinal cells, the CaSR modulates intestinal fluid secretion and mucosal integrity. Applying nutraceuticals that upregulate the CaSR may alleviate symptoms seen across a spectrum of illnesses. At last, we discuss how nanoparticle technology can be implemented to effectively deliver nutraceuticals to diseased regions of the intestine, thereby minimizing systemic side effects.